Evidence map›Paper›PMID 32111305›Full record

ArticlePoultry science2020

Protective efficacy of the Newcastle disease virus genotype VII-matched vaccine in commercial layers.

Hesham A Sultan, Shaimaa Talaat, Wael K Elfeil, Karim Selim, Mohamed A Kutkat, Sameh A Amer, Kang-Seuk Choi

Open access · goldAbstract read
In one paragraph

Article in Poultry science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Hesham A SultanDepartment of Birds and Rabbits Medicine, Faculty of Veterinary Medicine, Sadat City University, Menoufiya 32958, Egypt; Animal and Plant Quarantine Agency, Gimcheon, Republic of Korea. Electronic address: Sukkara@gmail.com.
Shaimaa TalaatDepartment of Birds and Rabbits Medicine, Faculty of Veterinary Medicine, Sadat City University, Menoufiya 32958, Egypt.
Wael K ElfeilAvian and Rabbit Medicine Department, Faculty of Veterinary Medicine, Suez Canal University, Ismailia, Egypt.
Karim SelimVirology Division, Animal Health Research Institute, Agriculture Research Centre, Dokki, Egypt.
Mohamed A KutkatVeterinary Research Division, National Research Centre, Dokki 12622, Cairo, Egypt.
Sameh A AmerVeterinary Research Division, National Research Centre, Dokki 12622, Cairo, Egypt.
Kang-Seuk ChoiAnimal and Plant Quarantine Agency, Gimcheon, Republic of Korea.
National Research Centre · EGUniversity of Sadat City · EGAnimal and Plant Quarantine Agency · KRSuez Canal University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Newcastle disease virus (NDV) is a major threat to the poultry industry worldwide, with a diversity of genotypes associated with severe economic losses in all poultry sectors. Class II genotype VII NDV are predominant in the Middle East and Asia, despite intensive vaccination programs using conventional live and inactivated NDV vaccines. In Egypt, the disease is continuously spreading, causing severe economical losses in the poultry industry. In this study; the protective efficacy of a commercial, inactivated recombinant genotype VII NDV-matched vaccine (KBNP-C4152R2L strain) against challenge with the velogenic NDV strain (Chicken/USC/Egypt/2015) was evaluated in commercial layers. Two vaccination regimes were used; live NDV genotype II (LaSota) vaccine on days 10, 18, and 120, with either the inactivated NDV genotype II regime or inactivated NDV genotype VII-matched vaccine regime on days 14, 42, and 120. The 2 regimes were challenged at the peak of egg production on week 26. Protection by the 2 regimes was evaluated after experimental infection, based on mortality rate, clinical signs, gross lesions, virus shedding, seroconversion, and egg production schedule. The results show that these 2 vaccination regimes protected commercial layer chickens against mortality, but some birds showed mild clinical signs and reduced egg production temporarily. However, the combination of live NDV genotype II and recombinant inactivated genotype VII vaccines provided better protection against virus shedding (20% and 0% vs. 60% and 40%) as assessed in tracheal swabs and (20% and 0% vs. 20% and 20%) in cloacal swabs collected at 3 and 5 D post challenge (dpc), respectively. In addition, egg production levels in birds receiving the inactivated NDV genotype VII-matched vaccine regime and in those given inactivated genotype II vaccines were 76.6, 79, 82, and 87.4% and 77.7, 72.5, 69, and 82.5% at 7, 14, 21, and 28 dpc, respectively. The results of this study indicate that recombinant genotype-matched inactivated vaccine along with a live attenuated vaccine can reduce virus shedding and improve egg production in commercial layers challenged with a velogenic genotype VII virus under field conditions. This regime may ensure a proper control strategy in layers.

Indexed as

AnimalsChickensEgyptFemaleGenotypeNewcastle DiseaseNewcastle disease virusPoultry DiseasesVaccinationVaccines, AttenuatedVaccines, SyntheticViral VaccinesVaccines, AttenuatedVaccines, SyntheticViral Vaccinesgenotype-matched vaccinegenotype VIIlayerNewcastle disease virus

Identifiers

PMID32111305
PMCPMC7587656
OpenAlexW3003815042

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.